MCID: CCN002
MIFTS: 51

Cocaine Abuse

Categories: Mental diseases

Aliases & Classifications for Cocaine Abuse

MalaCards integrated aliases for Cocaine Abuse:

Name: Cocaine Abuse 12 56 15 74
Cocaine-Related Disorders 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:809
ICD9CM 36 305.6 305.60
MeSH 45 D019970
SNOMED-CT 69 78267003
ICD10 34 F14.1

Summaries for Cocaine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cocaine despite negative consequences.

MalaCards based summary : Cocaine Abuse, also known as cocaine-related disorders, is related to eating disorder and peripartum cardiomyopathy. An important gene associated with Cocaine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Neuroscience. The drugs Dopamine and Caffeine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Cocaine Abuse

Diseases related to Cocaine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 eating disorder 30.4 DRD2 SLC6A3 SLC6A4
2 peripartum cardiomyopathy 30.2 DRD2 PRL
3 personality disorder 30.1 DRD2 PRL SLC6A3 SLC6A4
4 antisocial personality disorder 30.0 DRD2 SLC6A3 SLC6A4
5 sexual disorder 30.0 PRL SLC6A4
6 cocaine dependence 30.0 DBH DRD2 SLC6A3 SLC6A4
7 alcohol abuse 30.0 DRD2 PRL SLC6A4
8 alcohol dependence 29.9 DBH DRD2 HTR3A SLC6A3 SLC6A4
9 substance abuse 29.9 DBH DRD2 PRL SLC6A3 SLC6A4
10 bipolar disorder 29.9 DRD2 SLC18A2 SLC6A3 SLC6A4
11 panic disorder 29.8 HTR3A SLC6A2 SLC6A4
12 conduct disorder 29.8 DBH DRD2 SLC6A3 SLC6A4
13 attention deficit-hyperactivity disorder 29.5 DBH DRD2 SLC18A2 SLC6A2 SLC6A3 SLC6A4
14 disease of mental health 29.5 DRD2 SLC6A2 SLC6A3 SLC6A4 SNCA
15 schizophrenia 28.9 DBH DRD2 HTR3A PRL SLC18A2 SLC6A2
16 myocardial infarction 10.4
17 galactorrhea 10.3 DRD2 PRL
18 schizophreniform disorder 10.3 DRD2 PRL
19 prolactin producing pituitary tumor 10.3 DRD2 PRL
20 ischemia 10.3
21 functioning pituitary adenoma 10.3 DRD2 PRL
22 periodic limb movement disorder 10.3 DRD2 SLC6A4
23 rem sleep behavior disorder 10.3 SLC6A3 SNCA
24 alexithymia 10.3 DRD2 SLC6A4
25 thrombosis 10.2
26 vasculitis 10.2
27 intermittent explosive disorder 10.2 PRL SLC6A4
28 alcohol-induced mental disorder 10.2 DRD2 SLC6A3 SLC6A4
29 alcoholic psychosis 10.2 DRD2 SLC6A3 SLC6A4
30 acute myocardial infarction 10.2
31 pathological gambling 10.2 DRD2 SLC6A3 SLC6A4
32 amphetamine abuse 10.2 SLC6A2 SLC6A3
33 agoraphobia 10.2 SLC6A2 SLC6A4
34 striatonigral degeneration 10.2 DRD2 SLC6A3 SNCA
35 migraine without aura 10.2 DRD2 PRL SLC6A4
36 separation anxiety disorder 10.2 PRL SLC6A3
37 dilated cardiomyopathy 10.2
38 sinusitis 10.2
39 substance dependence 10.2 DRD2 SLC6A3 SLC6A4
40 schizoaffective disorder 10.2 DRD2 PRL SLC6A4
41 tobacco addiction 10.2 DRD2 SLC6A3 SLC6A4
42 stuttering 10.2 DBH DRD2 SLC6A3
43 tic disorder 10.2 DRD2 SLC18A2 SLC6A3
44 specific developmental disorder 10.1 SLC6A2 SLC6A3 SLC6A4
45 premature ejaculation 10.1 HTR3A SLC6A3 SLC6A4
46 migraine with aura 10.1 DBH DRD2 SLC6A4
47 pol iii-related leukodystrophies 10.1
48 neuroleptic malignant syndrome 10.1
49 hard palate cancer 10.1
50 placental abruption 10.1

Comorbidity relations with Cocaine Abuse via Phenotypic Disease Network (PDN):


Alcohol Abuse

Graphical network of the top 20 diseases related to Cocaine Abuse:



Diseases related to Cocaine Abuse

Symptoms & Phenotypes for Cocaine Abuse

MGI Mouse Phenotypes related to Cocaine Abuse:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.17 CARTPT DBH DRD2 HTR3A PRL SLC17A8
2 homeostasis/metabolism MP:0005376 10.06 BCHE CARTPT DBH DRD2 HTR3A PRL
3 growth/size/body region MP:0005378 10.02 CARTPT DBH DRD2 HTR3A SLC18A2 SLC6A2
4 endocrine/exocrine gland MP:0005379 10.01 CARTPT DBH DRD2 HTR3A PRL SLC6A3
5 integument MP:0010771 9.91 DBH DRD2 HTR3A PRL SLC17A8 SLC6A2
6 mortality/aging MP:0010768 9.81 BCHE DBH DRD2 HTR3A SLC18A2 SLC6A2
7 nervous system MP:0003631 9.65 DBH DRD2 HTR3A PRL SLC17A8 SLC18A2
8 taste/olfaction MP:0005394 9.02 DRD2 GRK3 SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Cocaine Abuse

Drugs for Cocaine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 329)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
2
Caffeine Approved Phase 4,Phase 2,Phase 3,Phase 1 58-08-2 2519
3
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-36-2 446220 5760
4
Biperiden Approved, Investigational Phase 4,Phase 2,Phase 3 514-65-8 2381
5
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
6
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 64-17-5 702
7
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
8
Disulfiram Approved Phase 4,Phase 2,Phase 1,Not Applicable 97-77-8 3117
9
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 300-62-9 3007 5826
10
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 113-45-1 4158
11
Amantadine Approved Phase 4,Phase 2,Phase 1 768-94-5 2130
12
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
13
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
14
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
15
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
16
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 1,Early Phase 1 56-86-0 33032
17
Choline Approved, Nutraceutical Phase 4,Phase 3 62-49-7 305
18
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable 7440-70-2 271
19 Raclopride Investigational Phase 4,Not Applicable,Early Phase 1 84225-95-6
20 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1
21 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Purinergic P1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
26 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
27 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
29 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Biperiden lactate Phase 4,Phase 2,Phase 3
35 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
37 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
38 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Free Radical Scavengers Phase 4,Phase 2,Phase 1,Early Phase 1
43 N-monoacetylcystine Phase 4,Phase 2,Phase 1,Early Phase 1
44 Expectorants Phase 4,Phase 2,Phase 1,Early Phase 1
45 Antidotes Phase 4,Phase 2,Phase 1,Early Phase 1
46 Antiviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
47 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antioxidants Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
49 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 408)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
3 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
4 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
5 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4 quetiapine
6 Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11 Completed NCT00015301 Phase 4 Methylphenidate
7 Modeling Impaired Judgement in Cocaine Abusers - 6 Completed NCT00015236 Phase 4
8 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4 Carbamazepine
9 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4 N-Acetylcystein;Placebo
10 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
11 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4 Lamotrigine;Placebo
12 An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
13 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
14 Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use Recruiting NCT02927236 Phase 4
15 Brain Imaging: Cocaine Effects & Medication Development - 5 Withdrawn NCT00000270 Phase 4 Cocaine
16 A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
17 Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1 Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
18 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
19 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
20 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3 Nefazodone
21 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
22 Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder Completed NCT00194129 Phase 3 Lithium;Divalproex;Placebo
23 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
24 Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed NCT00032929 Phase 3 Selegiline
25 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Completed NCT00000248 Phase 3 Pergolide
26 Combining Behavioral Treatment With Agonist Maintenance - 1 Completed NCT00000311 Phase 3 Buprenorphine;methadone
27 Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1 Completed NCT00000216 Phase 3 Buprenorphine
28 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
29 Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients. Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
30 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
31 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
32 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
33 Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
34 Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
35 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
36 Smoking-Cessation and Stimulant Treatment (S-CAST) Completed NCT01077024 Phase 3
37 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
38 Vigabatrin for the Treatment of Cocaine Dependency Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
39 Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
40 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1 Completed NCT00218660 Phase 3 Naltrexone;Placebo
41 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
42 Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1 Completed NCT00061087 Phase 2, Phase 3 Methylphenidate;Bupropion
43 Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
44 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
45 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
46 Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Unknown status NCT01259362 Phase 2
47 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
48 Study of the Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence Unknown status NCT01397266 Phase 2
49 Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Unknown status NCT01929343 Phase 2 lidocaine following cue-induced craving;lidocaine following neutral stimulus;saline
50 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine

Search NIH Clinical Center for Cocaine Abuse

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: cocaine-related disorders

Genetic Tests for Cocaine Abuse

Anatomical Context for Cocaine Abuse

MalaCards organs/tissues related to Cocaine Abuse:

42
Brain, Testes, Pituitary, Cortex, Liver, Prefrontal Cortex, Placenta

Publications for Cocaine Abuse

Articles related to Cocaine Abuse:

(show top 50) (show all 720)
# Title Authors Year
1
Chemogenetic Manipulations of Ventral Tegmental Area Dopamine Neurons Reveal Multifaceted Roles in Cocaine Abuse. ( 30446532 )
2019
2
Cocaine abuse and midbrain circuits: functional anatomy of hypocretin/orexin transmission and therapeutic prospect. ( 30796894 )
2019
3
Comments to: Valsalva retinopathy associated with intranasal cocaine abuse: A case report. ( 30945570 )
2019
4
Quadricuspid Aortic Valve Or a Rare Complication of Cocaine Abuse? ( 29122430 )
2018
5
Moyamoya tipping point: fatal bilateral MCA territory infarction following cocaine abuse. ( 29351941 )
2018
6
Cocaine abuse: Longitudinal MR imaging of lasting diffused leukoencephalopathy. ( 29400600 )
2018
7
Hypocretin/orexin deficiency decreases cocaine abuse liability. ( 29454841 )
2018
8
Mucocutaneous manifestations of cocaine abuse: a review. ( 29512202 )
2018
9
Aortic dissection in cocaine abuse: A fatal case. ( 30005338 )
2018
10
From Traumatic Childhood to Cocaine Abuse: The Critical Function of the Immune System. ( 30029767 )
2018
11
Valsalva retinopathy associated with intranasal cocaine abuse: A case report. ( 30207173 )
2018
12
Activation of the Immune System During a Developmental Window May Provide a Link Between Early Life Stress and Future Susceptibility to Cocaine Abuse. ( 30466507 )
2018
13
A tip from the nose: rhinocerebral mucormycosis in a patient with alcoholic liver cirrhosis and cocaine abuse, an uncommon association. ( 28784893 )
2017
14
Behaviour of hygrine and cuscohygrine in illicit cocaine production establishes their use as markers for chewing coca leaves in contrast with cocaine abuse. ( 27004438 )
2017
15
Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse. ( 27250583 )
2017
16
Impact on Cortical Function of Cocaine Abuse Co-Occurring with HIV. ( 27909321 )
2017
17
Cocaine abuse determination by ion mobility spectrometry using molecular imprinting. ( 28012589 )
2017
18
Resting state brain connectivity patterns before eventual relapse into cocaine abuse. ( 28057531 )
2017
19
Asymptomatic Cocaine Abuse - Myocardial Tissue Characterization Using Cardiac Biomarkers and Cardiovascular Magnetic Resonance Imaging. ( 28179611 )
2017
20
Internuclear Ophthalmoplegia Secondary to Cocaine Abuse. ( 28265477 )
2017
21
The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic. ( 28266501 )
2017
22
Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease. ( 28315271 )
2017
23
Botryoid nuclei resulting from cocaine abuse. ( 28439943 )
2017
24
Multi-System Complications after Intravenous Cocaine Abuse. ( 28507634 )
2017
25
Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis. ( 28590371 )
2017
26
Towards an automatic lab-on-valve-ion mobility spectrometric system for detection of cocaine abuse. ( 28712550 )
2017
27
Chronic orbital inflammatory disease and optic neuropathy associated with long-term intranasal cocaine abuse: 2 cases and literature review. ( 28812909 )
2017
28
The Use of Intraoperative Transesophageal Echocardiography in Thoracic Aortic Dissection Due to Chronic Cocaine Abuse. ( 28920034 )
2017
29
Heparan sulfate: Resilience factor and therapeutic target for cocaine abuse. ( 29066725 )
2017
30
Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. ( 27600990 )
2016
31
Cocaine abuse and effects in the serum levels of cytokines IL-6 and IL-10. ( 26679059 )
2016
32
The most dangerous complication of intranasal cocaine abuse in a young man: cardiac arrest. ( 26778640 )
2016
33
Cocaine and crack cocaine abuse by pregnant or lactating mothers and analysis of its biomarkers in meconium and breast milk by LC-MS-A review. ( 26827634 )
2016
34
Increased MFG-E8 expression and its implications in the vascular pathophysiology of cocaine abuse. ( 27182119 )
2016
35
Relationship between coronary artery ectasia, cocaine abuse and acute coronary syndromes. ( 27231522 )
2016
36
Plasma Selenium Levels in Chronic Cocaine Abuse. ( 27349018 )
2016
37
Extensive Necrotic Purpura in Levamisole-Adulterated Cocaine Abuse - A Case Report. ( 27500987 )
2016
38
A case of iloperidone overdose in a 27-year-old man with cocaine abuse. ( 27570623 )
2016
39
Cocaine abuse that presents with acute scrotal pain and mimics testicular torsion. ( 27583357 )
2016
40
The Ventral Pallidum: Proposed Integrator of Positive and Negative Factors in Cocaine Abuse. ( 27710789 )
2016
41
Plant expression of cocaine hydrolase-Fc fusion protein for treatment of cocaine abuse. ( 27756365 )
2016
42
Cocaine Abuse: An Unusual Association. ( 27805341 )
2016
43
Multiple Pyoderma Gangrenosum Ulcers Associated with Cocaine Abuse. ( 28003907 )
2016
44
Cocaine abuse, retiform purpura and antiphospholipid syndrome. ( 26070938 )
2015
45
Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. ( 24898775 )
2015
46
Facial cutaneous necrosis associated with suspected levamisole toxicity from tainted cocaine abuse. ( 25015925 )
2015
47
Prosthetic Management for a Palatal Perforation from Cocaine Abuse. ( 25557361 )
2015
48
Investigating the potential influence of cause of death and cocaine levels on the differential expression of genes associated with cocaine abuse. ( 25658879 )
2015
49
Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies. ( 25662894 )
2015
50
Neuropsychological impairments associated with the relation between cocaine abuse and violence: neurological facilitation mechanisms. ( 25879478 )
2015

Variations for Cocaine Abuse

Expression for Cocaine Abuse

Search GEO for disease gene expression data for Cocaine Abuse.

Pathways for Cocaine Abuse

Pathways related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 DRD2 GRK3 SLC17A8 SLC18A2 SLC6A3
2 12.16 CARTPT DBH GRK3 SNCA
4 11.81 SLC6A2 SLC6A3 SLC6A4
5
Show member pathways
11.7 DRD2 SLC18A2 SLC6A3
6
Show member pathways
11.69 SLC17A8 SLC18A2 SLC6A4
7 11.67 HTR3A SLC18A2 SLC6A4
8 11.02 SLC6A3 SNCA
9 10.97 SLC18A2 SLC6A3
10 10.88 HTR3A SLC18A2 SLC6A4
11
Show member pathways
10.76 BCHE SLC6A3 SLC6A4
12
Show member pathways
10.56 DBH SLC6A2 SLC6A3 SLC6A4
13 10.49 DBH SLC18A2 SLC6A2

GO Terms for Cocaine Abuse

Cellular components related to Cocaine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.88 DRD2 HTR3A SLC18A2 SLC6A2 SLC6A3 SLC6A4
2 neuronal cell body GO:0043025 9.76 HTR3A SLC17A8 SLC6A3 SNCA
3 axon GO:0030424 9.73 DRD2 HTR3A SLC6A3 SNCA
4 neuron projection GO:0043005 9.72 HTR3A SLC17A8 SLC6A2 SLC6A3 SLC6A4
5 membrane raft GO:0045121 9.65 SLC6A2 SLC6A3 SLC6A4
6 synaptic vesicle membrane GO:0030672 9.56 DRD2 SLC17A8 SLC18A2 SNCA
7 axon terminus GO:0043679 9.54 DRD2 SLC17A8 SNCA
8 dopaminergic synapse GO:0098691 9.33 DRD2 SLC18A2 SLC6A3
9 integral component of presynaptic membrane GO:0099056 9.26 DRD2 HTR3A SLC6A3 SLC6A4
10 integral component of postsynaptic membrane GO:0099055 8.92 DRD2 HTR3A SLC6A3 SLC6A4

Biological processes related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.93 SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
2 response to toxic substance GO:0009636 9.77 DRD2 SLC18A2 SLC6A4
3 chemical synaptic transmission GO:0007268 9.73 CARTPT DBH HTR3A SLC18A2 SLC6A2 SNCA
4 excitatory postsynaptic potential GO:0060079 9.7 DRD2 HTR3A SNCA
5 locomotory behavior GO:0007626 9.67 DBH DRD2 SLC18A2 SLC6A3
6 positive regulation of multicellular organism growth GO:0040018 9.65 DRD2 SLC6A3
7 associative learning GO:0008306 9.64 DBH DRD2
8 regulation of long-term neuronal synaptic plasticity GO:0048169 9.64 DRD2 SNCA
9 behavioral response to cocaine GO:0048148 9.63 DRD2 SNCA
10 response to pain GO:0048265 9.63 DBH SLC6A2
11 response to drug GO:0042493 9.63 BCHE DRD2 SLC6A2 SLC6A3 SLC6A4 SNCA
12 response to iron ion GO:0010039 9.62 DRD2 SLC6A3
13 synaptic transmission, dopaminergic GO:0001963 9.62 DRD2 SNCA
14 response to cocaine GO:0042220 9.62 DRD2 HTR3A SLC6A3 SNCA
15 dopamine metabolic process GO:0042417 9.61 DRD2 SNCA
16 prepulse inhibition GO:0060134 9.61 DRD2 SLC6A3
17 response to amphetamine GO:0001975 9.61 DBH DRD2 SLC18A2
18 neurotransmitter biosynthetic process GO:0042136 9.6 SLC6A3 SLC6A4
19 dopamine biosynthetic process GO:0042416 9.58 SLC6A3 SNCA
20 adenohypophysis development GO:0021984 9.58 DRD2 SLC6A3
21 response to ethanol GO:0045471 9.58 DRD2 HTR3A SLC6A3
22 behavioral response to ethanol GO:0048149 9.57 DBH DRD2
23 response to nutrient GO:0007584 9.56 BCHE SLC6A4
24 dopamine catabolic process GO:0042420 9.55 DBH SLC6A3
25 dopamine transport GO:0015872 9.51 SLC18A2 SLC6A3
26 neurotransmitter loading into synaptic vesicle GO:0098700 9.49 SLC17A8 SLC18A2
27 dopamine uptake involved in synaptic transmission GO:0051583 9.48 SLC6A2 SNCA
28 serotonin uptake GO:0051610 9.46 SLC18A2 SLC6A4
29 neurotransmitter transport GO:0006836 9.35 SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
30 monoamine transport GO:0015844 8.92 SLC18A2 SLC6A2 SLC6A3 SLC6A4

Molecular functions related to Cocaine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.46 SLC6A2 SNCA
2 symporter activity GO:0015293 9.46 SLC17A8 SLC6A2 SLC6A3 SLC6A4
3 alpha-tubulin binding GO:0043014 9.43 SLC6A2 SNCA
4 dopamine binding GO:0035240 9.4 DRD2 SLC6A3
5 serotonin binding GO:0051378 9.37 HTR3A SLC6A4
6 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A2 SLC6A3
7 serotonin:sodium symporter activity GO:0005335 9.26 SLC18A2 SLC6A4
8 neurotransmitter:sodium symporter activity GO:0005328 9.13 SLC6A2 SLC6A3 SLC6A4
9 monoamine transmembrane transporter activity GO:0008504 8.92 SLC18A2 SLC6A2 SLC6A3 SLC6A4

Sources for Cocaine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....